Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Rapport Therapeutics Inc.
312 participants
Jun 1, 2026
INTERVENTIONAL
Conditions
Summary
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RAP-219 medium dose tablets administered orally daily
RAP-219 low dose tablets administered orally daily
Matching placebo tablets administered orally
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07594119